FDA Places Clinical Hold on Agios’ Development Anemia Disorder Drug

Agios is discontinuing the development of an anemia disorder drug after the FDA placed a clinical hold on trials for the candidate, prompting the company shift its focus to another candidate.

The FDA’s decision to stop the clinical trials came after a subject developed liver disease while taking a 300mg tablet of the candidate.

The company plans to work on developing a less potent anemia disorder candidate that has proven more successful candidate in studies.